Global Health Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Revenue growth above 20%EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

MEDANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹1210.30

prior close

₹1234.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.4%+2.7% vs market

Hospital peers, median of 26sector-0.3%+2.5% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Midcap 150 and 2.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.5

15m

+0.3

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3-0.4+2.7-0.3+2.5

Next day

+2.4-0.7+3.1-1.1+3.5

+2.0+0.1+1.9+1.3+0.7

+1.9+0.4+1.4+1.0+0.9

+2.5+0.5+2.0+0.8+1.8

+2.1+0.7+1.5+1.2+0.9

+1.5+2.0-0.5+1.1+0.4

15d

-0.0-1.9+1.9+2.1-2.1

+0.3+1.0-0.8+1.5-1.3

+10.9+3.6+7.3+5.0+5.9

+17.0+4.9+12.1+7.0+10.0

UpDownMarket · Nifty Midcap 150Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Global Health Limited (Medanta) reported consolidated revenue of ₹44,103 million for FY2026, up 19.4% from ₹36,923 million in FY2025. PAT grew 15.1% to ₹5,541 million from ₹4,813 million. The board recommended a final dividend of ₹0.50 per equity share (25% payout on face value of ₹2). Auditors Walker Chandiok & Co LLP issued an unmodified audit opinion with no qualifications. Exceptional items of ₹10.21 million were recorded (net reversal of EPCG and stamp duty, partially offset by ₹365.98 million impact of new labour codes). The company also announced expansion plans including a 400-bed hospital in Varanasi and acquisition of a 79-bed oncology hospital in Indore.

Likely market impact

Revenue growth of ~19.4% is strong but slightly below the 20% threshold. PAT growth of 15% is decent but below expectations. The EBITDA margin compression (estimated at ~62 bps YoY) is a minor concern, while the clean audit opinion and dividend declaration are positives for shareholders.